India’s highest court is set to hear a long-running dispute between Novartis and the country’s government, which has prevented the pharma company from patenting its cancer drug Gleevec.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Novartis, pharmaceuticals, Gleevec, healthcare, India Patent Act
